Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMar 12, 2018	Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results PRINCETON, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months and year ended December 31, 2017 and provided a corporate update. Fourth quarter 2017 and other recent corporate...	Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 27.3 KB
Toggle SummaryMar 14, 2018	Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for AG200-15 (Twirla ® ), an investigational, once-weekly, low-dose hormonal contraceptive patch, has been...	Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition 14.8 KB
Toggle SummaryMay 7, 2018	Agile Therapeutics Reports First Quarter 2018 Financial Results PRINCETON, N.J., May 07, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2018 and provided a corporate update. First quarter 2018 and other recent corporate developments include:...	Agile Therapeutics Reports First Quarter 2018 Financial Results 25.8 KB
Toggle SummaryMay 18, 2018	Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy PRINCETON, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company, today announced the content of the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) held on April 16, 2018 to discuss the complete...	Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy 16.9 KB
Toggle SummaryJun 7, 2018	Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , June 07, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX), a women’s healthcare company, today announced several key corporate updates: Formal dispute resolution request has been...	Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance 26.1 KB
Toggle SummaryJul 24, 2018	FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request Company Plans to Appeal to the FDA’s Office of New Drugs PRINCETON, N.J. , July 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX) (the “Company”), a women’s healthcare company, today announced that the Office Director of the FDA’s Office of Drug Evaluation III (ODEIII) has...	FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request 23.4 KB
Toggle SummaryAug 3, 2018	Agile Therapeutics Reports Second Quarter 2018 Financial Results Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and six months ended June 30, 2018 and provided a...	Agile Therapeutics Reports Second Quarter 2018 Financial Results 81 KB
Toggle SummaryOct 9, 2018	Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA PRINCETON, N.J. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has received a response from FDA’s Office of New Drugs (“OND”) concerning the Company’s formal dispute resolution request. The Company had appealed...	Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA 36.3 KB
Toggle SummaryOct 24, 2018	Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) PRINCETON, N.J. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced an oral presentation regarding predictors of pregnancy in the Phase 3 SECURE study of the investigational low-dose, once-weekly contraceptive patch,...	Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) 34.3 KB
Toggle SummaryNov 1, 2018	Agile Therapeutics Reports Third Quarter 2018 Financial Results Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and nine months ended September 30, 2018 and...	Agile Therapeutics Reports Third Quarter 2018 Financial Results 95.1 KB